로딩 중…
지수 로딩 중…
Yarrow Bioscience Inc. Common Stock
YARW· NASDAQ
$27.01-5.03%
2026-09-11
Financials
Valuation Metrics
Yarrow Bioscience Inc. Common Stock's Market Cap is $23M. At end of 2025 it was $0M. Ranked #3110 of 3,118 in US market (top 100%), #1453 of 1,460 on NASDAQ (top 100%) by Market Cap.
Investment Metrics(as of 2026-09-11)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $23M | US#3,110/3,118 |
| Revenue | $482000.00 | US#2,881/3,118 |
| Net Income | $-19M | US—/3,118 |
| Total Assets | $24M | US#3,093/3,118 |
| Net Assets | $22M | US#2,899/3,118 |
| Employees | 10 | US#2,789/3,118 |
| Value | ||
| P/B | 1.05x | US#475/3,118 |
| P/S | 48.18x | US#2,924/3,118 |
| FCF Yield | -72.92% | US—/3,118 |
| Profitability | ||
| ROE | -84.80% | US#2,783/3,118 |
| ROA | -79.26% | US#3,050/3,118 |
| Op. Margin | -4134.65% | US#2,858/3,118 |
| Revenue Growth | 13.77% | US#931/3,118 |
| Financial Health | ||
| Debt Ratio | 6.99% | US#64/3,118 |
| Total Debt | $0.00 | US—/3,118 |
| FCF | $-17M | US#2,409/3,118 |
| Cash | $23M | US#2,842/3,118 |
| Current Ratio | 15.26x | US#166/3,118 |
| Performance | ||
| 1Y Return | 71.17% | US#287/3,118 |
| 1M Return | -36.85% | US#3,080/3,118 |
| From 52W High | -42.47% | US#2,457/3,118 |
| 1Y MDD | -44.85% | US#2,241/3,118 |
| Trading | ||
| Volume | 1,359,222 shares | US#3,062/3,118 |
| Trading Value | $36M | US#2,985/3,118 |
| Per Share | ||
| EPS | $-21.76 | US—/3,118 |
| BPS | $25.66 | US#1,023/3,118 |
Company Info
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).